The promise of epigenetic therapies in treatment of idiopathic pulmonary fibrosis

American Journal of Respiratory and Critical Care Medicine

Volumn 187, Issue 4, 2013, Pages 336-338

  Rosas, Ivan O ^a,b,c   Yang, Ivana V ^d,e,f  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^e DEPARTMENT OF MEDICINE   (United States)

^f Global Health and Health Disparities   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CIGARETTE SMOKE; COLLAGEN; CONNECTIVE TISSUE GROWTH FACTOR; CPG OLIGODEOXYNUCLEOTIDE; DNA METHYLTRANSFERASE 1; HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA; METHYLTRANSFERASE INHIBITOR; TRANSFORMING GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

AIRWAY REMODELING; CORRELATION ANALYSIS; CPG ISLAND; DISEASE SEVERITY; DNA METHYLATION; DNA SEQUENCE; EDITORIAL; ENVIRONMENTAL FACTOR; EPIGENETIC THERAPY; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; FIBROBLAST; FIBROSING ALVEOLITIS; FOOD AND DRUG ADMINISTRATION; GENE CONTROL; GENE EXPRESSION; GENE INTERACTION; GENE THERAPY; GENETIC TRANSCRIPTION; GENOMICS; HOMEOSTASIS; HUMAN; LUNG ALVEOLUS EPITHELIUM; LUNG FIBROBLAST; LUNG FIBROSIS; MYOFIBROBLAST; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; UPREGULATION; WOUND HEALING;

ANIMALS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MICRORNAS;

EID: 84873967056     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201212-2272ED     Document Type: Editorial

References (23)

1. Olson AL, Swigris JJ, Lezotte DC, Norris JM, Wilson CG, Brown KK. Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med 2007;176:277-284.
2. Garcia CK. Idiopathic pulmonary fibrosis: update on genetic discoveries. Proc Am Thorac Soc 2011;8:158-162.
3. Taskar VS, Coultas DB. Is idiopathic pulmonary fibrosis an environmental disease? Proc Am Thorac Soc 2006;3:293-298.
4. King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet 2011;378:1949-1961.
5. Kass DJ, Kaminski N. Evolving genomic approaches to idiopathic pulmonary fibrosis: moving beyond genes. Clin Transl Sci 2011;4:372-379.
6. Yang IV, Schwartz DA. Epigenetic control of gene expression in the lung. Am J Respir Crit Care Med 2011;183:1295-1301.
7. Yang IV. Epigenomics of idiopathic pulmonary fibrosis. Epigenomics 2012;4:195-203.
8. Pandit KV, Milosevic J, Kaminski N. MicroRNAs in idiopathic pulmonary fibrosis. Transl Res 2011;157:191-199.
9. Rabinovich EI, Selman M, Kaminski N. Epigenomics of idiopathic pulmonary fibrosis: evaluating the first steps. Am J Respir Crit Care Med 2012;186:473-475.
10. Rabinovich E, Yakhini Z, Benos P, Pandit K, Milosevic J, Kapetanak M, Richards T, Chensny L, Kaminski N. Human CpG islands arrays reveal changes in global methylation patterns in idiopathic pulmonary fibrosis. PLoS ONE 2012;7:e33770.
11. Sanders YY, Ambalavanan N, Halloran B, Zhang X, Liu H, Crossman DK, Bray M, Zhang K, Thannickal VJ, Hagood JS. Altered DNA methylation profile in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012;186:525-535.
12. Dakhlallah D, Batte K, Wang Y, Cantemir-Stone CZ, Yan P, Nuovo G, Mikhail A, Hitchcock CL, Wright VP, Nana-Sinkam SP, et al. Epigenetic regulation of miR-17w92 contributes to the pathogenesis of pulmonary fibrosis. Am J Respir Crit Care Med 2013;187:397-405.
13. Concepcion CP, Bonetti C, Ventura A. The microRNA-17-92 family of microRNA clusters in development and disease. Cancer J 2012;18:262-267.
14. Butz H, Racz K, Hunyady L, Patocs A. Crosstalk between TGF-beta signaling and the microRNA machinery. Trends Pharmacol Sci 2012;33:382-393.
15. Issa JP, Kantarjian HM. Targeting DNA methylation. Clin Cancer Res 2009;15:3938-3946.
16. Kaminskas E, Farrell AT, Wang YC, Sridhara R, Pazdur R. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist 2005;10:176-182.
17. Saba HI. Decitabine in the treatment of myelodysplastic syndromes. Ther Clin Risk Manag 2007;3:807-817.
18. Amatori S, Bagaloni I, Donati B, Fanelli M. DNA demethylating antineoplastic strategies: a comparative point of view. Genes Cancer 2010; 1:197-209.
19. Brock MV, Hooker CM, Ota-Machida E, Han Y, Guo M, Ames S, Glockner S, Piantadosi S, Gabrielson E, Pridham G, et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 2008;358:1118-1128.
20. Juergens RA, Wrangle J, Vendetti FP, Murphy SC, Zhao M, Coleman B, Sebree R, Rodgers K, Hooker CM, Franco N, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov 2011;1:598-607.
21. Gaudet F, Hodgson JG, Eden A, Jackson-Grusby L, Dausman J, Gray JW, Leonhardt H, Jaenisch R. Induction of tumors in mice by genomic hypomethylation. Science 2003;300:489-492.
22. You JS, Jones PA. Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell 2012;22:9-20.
23. Heard E, Tishkoff S, Todd JA, Vidal M, Wagner GP, Wang J, Weigel D, Young R. Ten years of genetics and genomics: what have we achieved and where are we heading? Nat Rev Genet 2010;11:723-733.